Introduction
The value of high-dose chemotherapy with autologous hematopoietic cell transplantation has been recently questioned as a treatment modality for high-risk or advanced breast cancer, due to early results of randomized studies [1, 2] . However, long-term remissions have been achieved with this approach in advanced disease, and in high-risk patients with more than ten involved axillary nodes [3] [4] [5] . It is still not clear if post-transplant relapse is due to persistence of systemic disease, infusion of clonogenic tumor cells, or a combination of both causes. With the aim of investigating the role of minimal residual disease (MRD) in breast cancer patients, a variety of assays have been developed. Immunocytochemical staining and flow cytometry, using a panel of monoclonal antibodies directed against cell surface glycoproteins or cytokeratins, have shown that both bone marrow (BM) and peripheral blood progenitor cells (PBPC) collected after high-dose chemotherapy may contain residual tumor cells. These techniques have a sensitivity detection of one cancer cell in up to 10 3 -10 4 normal hematopoietic cells [6] [7] [8] [9] . The presence of occult cytokeratin-positive metastatic cells in the bone marrow of patients with stage I-III breast cancer has recently been reported to predict distant relapse rate and death from breast cancer [10] . Thus, the detection of MRD by immunocytochemistry may be relevant for the prognosis of breast cancer. Recently, several reverse-transcriptase polymerase chain reaction (RT-PCR) assays have been developed to improve the sensitivity of the detection of breast micrometastases in BM, peripheral blood (PB), and PBPC [11] [12] [13] [14] [15] . The optimal approach for the RT-PCR detection of circulating breast cancer cells would be the amplification of tissue-specific RNA transcripts not expressed in normal hematopoietic tissues. A number of breast cancer markers have been reported in the literature, and many of them have shown important limitations for their use in the clinical setting. , an intermediate filament protein expressed by all simple epithelia and by a small number of other tissues, has been originally presented as a promising, specific and sensitive marker for the detection of breast cancer cells in axillary lymph nodes, PB and BM [7] . The reported value of the RT-PCR based assay for CK-19 was sub-sequently questioned because of the documented expression of this gene in either PB or lymph nodes of normal subjects [16] . Mucin-1 (MUC-1), cytokeratin 20 (CK-20), carcinoembryonic antigen (CEA) and maspin have been reported to be sensitive RT-PCR markers for cancer cell detection in patients with breast cancer; however, several studies refer MUC-1, CK-20, and CEA mRNA expression in the lymph nodes, PB and/or BM of patients with no evidence of breast cancer [16] [17] [18] [19] [20] . Recently, Hildebrandt et al. reported epidermal growth factor receptor (EGFR) as a reliable mRNA marker of breast cancer with a high specificity and sensitivity [21] . More recently mammaglobin, a tissue specific mRNA marker expressed in adult mammary tissues and in 80%-90% primary breast tumors, has been detected in over 60% of the lymph nodes of patients with metastatic breast cancer, but not in the normal lymph nodes from non-cancer patients [18, 22] . These results indicate mammaglobin as a hypothetical optimal marker for the detection of circulating breast cancer cells [23] .
The aim of our study was to determine the sensitivity and specificity of CK-19, CK20, MUC-1, EGFR, CEA, maspin and mammaglobin markers in detecting breast cancer cells by RT-PCR.
Patients and methods

Cell lines and patient samples
Human breast cancer cell lines MCF-7 (estrogen receptor-positive) and SKBR3 (estrogen receptor-negative) obtained from the American Type Culture Collection (Rockville, Maryland) were used in the development of the RT-PCR assays. The tumor samples analyzed consisted of 30 surgical specimens from patients with histologic diagnosis of breast cancer (Table I) . BM, PB, and PBPC were obtained from a study population of 38 breast cancer patients undergoing high-dose chemotherapy as an adjuvant treatment for high-risk disease (i.e.. more than ten involved axillary nodes), or as a salvage treatment for advanced disease. The study protocols were approved by the local IRB, and patients gave their informed consent to the study. All breast tissues were obtained from surgical resection specimens snap-frozen in liquid nitrogen within 10 minutes of their arrival in the pathology specimen reception area, and kept frozen until tissue homogenization prior to extraction Ten normal PB, 12 normal BM and 2 normal PBPC were obtained from healthy donors. Four PB, 8 BM and 12 leukapheresis samples were collected from patients with hematological malignancies (lymphoma, multiple myeloma and leukemias). To avoid potential contamination from skin epithelial cells, the first 1 ml of PB and 0.5 ml of BM aspirates were stored, and not used for PCR analysis Samples were processed as described below.
To determine the sensitivity of the assays, peripheral blood mononuclear cells (PB) obtained from a normal donor were mixed with decreasing numbers of MCF-7 cells or SKBR3 cells. Cells were mixed before the RNA preparation, thus mimicking the clinical setting for detection of tumor cells in the PB or BM of patients.
RNA preparation
Cells were separated on a Ficoll-Hypaque density gradient. Ten million mononuclear cells obtained from PB, BM, leukapheresis samples and breast tissues homogenates were lysed in TRIZOL reagent (GIBCO-BRL, Gaithersburg. Maryland) and sheared to homogeneity, following the one-step guanidinium isothiocyanate/phenol RNA preparation as 
originally described [24] . RNA was precipitated in isopropanol, washed in 70% ethanol. and resuspended in RNAse-free water. To eliminate contaminating DNA. RNA was exposed to RNAse-free DNAse I (I U/ug RNA; Promega, Madison, Wisconsin) at 37 °C for 10 minutes. After heat inactivation of the enzyme at 95 °C for five minutes, RNA was reprecipitated and resuspended.
cDNA synthesis and PCR amplification Total RNA was reverse transcribed into total cDNA using an oligo-dT primer (Promega, Madison, Wisconsin). Five ug of total RNA was incubated with 50 ng of oligo-dT primer at 70 °C for 10 minutes. A 50 ul reaction was performed in 10 mM dNTPs (Pharmacia LKB Biotechnology, Uppsala, Sweden), 10 mM DTT, 1 x reverse transcriptase buffer (50 mM Tris Hcl, 6 mM MgCl 2 ,40 mmmol/1 Kcl) final concentration, adding 20 U of ribonuclease inhibitor (RNAsin; Promega, Madison, Wisconsin), and 200 U Moloney murine leukemia virus reverse transcriptase (Superscript; GIBCO BRL. Gaithersburg, Maryland). The reaction mixture was incubated for one hour at 37 °C. Reverse-transcriptase was heat inactivated at 95 °C for five minutes. Two ul of each reaction product were analyzed by nested-PCR.
The cDNA was amplified in 200 nmol/1 dNTPs, 1 x Taq buffer [50 mmol/1 Kcl, 10 mmol/1 Tris/HCl pH, I mmol/1 MgCl 2 , 1% (wt/vol) gelatin] final concentration, adding 2,5 U of Taq DNA polymerase (Promega) and from 10 to 20 pmol of primers in a final volume of 50 ul Nested RT-PCRs were performed using published primer sequences as described for CK-19. CEA and maspin [12, 13, 17] . MUC-1, EGFR, CK-20 and mammaglobin nested RT-PCR were performed using first round published primer sequences [18, 21, 25, 26] and second-round internal primers designed during the study (for MUC-1: MUC-lc 5'-CAAGCTCTACCCCAGGTG-3' and MUC-ld 5'-GAC-AATGGCCAGCGGCAAC-3'; for EGFR: EGFR3 5'-TCTCAGCA-ACATGTCGATGG-3' and EGFR4 5'-TCGCACT-TCTTACACTT-GCG-3', for CK-20: CK20a 5'-GCAGATTCGGAGTAACATGGA-3' and CK20d 5'-GCACGACTGTCTTAATCTTGG-3'; for mammaglobin: MG3 5'-GAGTTCATAGACGACAATGCC-3' and MG4 5'-CCGTAGTTGGTTTCTCACCAT-3'. -20, 199 bp for mammaglobin and 131 bp for CEA. All the specimens were tested for the presence of intact RNA, adequate cDNA synthesis, and absence of inhibitors by amplifying p 2 microglobulin gene using a single step PCR. All primer pairs were used to amplify genomic DNA and gave no products, confirming that primer choice and DNAse treatment were effective.
Results
Assay sensitivity and negative controls
To determine the sensitivity of RT-PCR assays, 1 million PB mononuclear cells obtained from a normal donor were mixed with decreasing numbers of MCF-7 and SKBR-3 cell lines (for the last dilution 10 breast cancer cells were diluted in 10 million normal cells). RNA was isolated and RT-PCR analysis performed as described in the methods section. The sensitivity for all assays was satisfactory, and the detection limit ranged between 1 to 10 MCF-7 or SKBR-3 cells in one million PB cells. Results on specificity are shown in detail in Table 2 . In our study, 3 out of 10 PB from healthy subjects expressed CK-19 and all the healthy individuals expressed the MUC-1 mRNA. The EGFR, CK-20, CEA, maspin and mammaglobin transcripts were not detected in PB samples from healthy donors. The expression of CK-19, CK-20, MUC-1, EGFR and CEA occurred at variable frequency in the BM cells obtained from Abbreviations: BC -breast cancer; BM -bone marrow; PB -peripheral blood; PBPC -peripheral blood progenitor cells.
cases of solid tumors other than breast were tested: maspin and mammaglobin transcripts were not detected.
To assess whether the treatment with G-CSF could alter the expression of such mRNA markers, we have tested mobilized PBPC from both healthy donors and patients with hematological tumors. All PBPC specimen were found negative for maspin, mammaglobin, CK-19 and EGFR transcripts, while MUC-1 CEA and CK-20 were expressed at variable frequency (Table 2) .
Marker expression in breast cancer patients and cell lines
The results of nested RT-PCR assays in breast cancers and cell lines are shown in Table 3 . MCF-7 and SKBR3 cell lines expressed all the mRNA markers. The expression of these markers in primary breast cancer cells ranged from 57% (CK-20) to 97% (mammaglobin). BM and PB cells were obtained from seven and five breast cancer patients, respectively; BM samples were negative for CK-19, CK-20 and maspin transcripts, while MUC-1, EGFR, CEA and mammaglobin were expressed at variable frequency (Table 3 ). The only markers that were expressed in the PB of breast cancer patients were MUC-1 and CEA.
Detection of residual breast cancer cells in PBPC harvests
In order to evaluate tumor cell contamination of PBPC harvests collected after high-dose chemotherapy, we performed RT-PCR on 38 apheresis products. Overall the expression of breast cancer markers was as follows: MUC-1 in 5 of 12 (42%) PBPC samples, maspin in 2 of 38 (5%), CEA in 6 of 37 (16 %), and mammaglobin in 3 of 37 (8%). None of PBPC samples were found positive for CK19 or EGFR transcripts (Table 3 ). In particular, RT-PCR on PBPC samples from patients with metastatic disease gave the following positive results: MUC-1, one case, CEA four cases, maspin two cases, and mammaglobin one case.
Discussion
Detection of breast cancer cells is possible by conventional immunocytochemistry, cell culture techniques, flow cytometry, and RT-PCR amplification of epithelial-specific mRNA sequences. The major advantage of RT-PCR over the other methods is the operator independency, the possibility of permanent documentation and the sensitivity. Recently published data show that occult breast cancer cells have been detected by RT-PCR in the PB of 15% to 30% of patients, in the BM aspirates of 50% to 60% of patients, in axillary lymph nodes (without overt metastases) of 3% to 55% of patients [6, 7, 13, 14, 21] .
A major concern in the use of RT-PCR assays arises from the conflicting data reported in the literature on the specificity of different assays. The specificity of the RT-PCR techniques is basically abrogated when the mRNA marker is expressed by the normal hematopoietic cells. Several studies have reported the expression of CK-19, MUC-1, CK-20 and CEA in PB, BM and lymph nodes of patients with breast cancer, leading to the conclusion that tumor cells were circulating [7, 9, 12, 13, 17] . On the other hand, recent reports have indicated that these molecular markers are also expressed by normal cells [8, 9, 12] . Our study shows that CK-19, MUC-1, CK-20, EGFR and CEA transcripts are detected in PB or BM of healthy subjects, and in patients with hematological malignancies, thus they seem not specific enough to be used for the detection of occult breast cancer cells (Table 2) . Maspin, a protein related to the serpin family of protease inhibitors, and mammaglobin, a tissue-specific marker expressed in adult mammary tissue, have been recently reported as specific markers for the detection of occult breast cancer cells [17, 18, 23, 27] . In our study, both these markers were not detected in PB and BM from healthy subjects or from patients with hematological malignancies. Our results confirm that maspin and mammaglobin are sensitive and specific markers for the detection of occult breast cancer cells (Table 2) .
In autografting procedure, the presence of residual tumor cells remains a major concern, since some authors have described the presence of contaminating tumor cells in PBPC harvests used to support the hematopoietic recovery after high-dose chemotherapy [7, 9] . It is currently unknown whether the reinfusion of grafts containing occult breast cancer cells contributes to disease relapse. However, the presence of gene-marked tumor cells at the site of disease relapse has been documented in other malignancies [28] . The developement of specific and sensitive methods for the detection of residual tumor cells would be useful to monitor the response to chemotherapy, the presence of occult cells in autografts and the efficiency of purging techniques.
Lopez-Guerrero et al. reported CEA and CK-19 to be specific and sensitive markers for detecting the presence of breast cancer cells in leukapheresis samples, and maspin to be a non-specific marker for the detection of tumor cells contamination in PBPC collections [29] . In our study, CK-19, and EGFR mRNA expression was not observed in PBPC harvests of breast cancer patients; while MUC-1, CK-20, maspin and mammaglobin rate mRNA expression ranged from 5% to 40% (Table 3) . In order to evaluate the specificity of the RT-PCR assays, marker expression was evaluated in PBPC from blood tumor patients. MUC-1, CK-20 and CEA transcripts were detected in PBPC samples from patients with blood tumors. In the same samples, CK-19, EGFR, maspin and mammaglobin transcripts were not detected ( Table 2) . We conclude that MUC-1, CK-19, CK-20, EGFR and CEA markers have a limited diagnostic applicability because of their expression in PB, BM and PBPC harvests of normal subjects or blood tumor patients. Hence, our data indicate that RT-PCR detection of breast cancer cells should be based on maspin and mammaglobin markers.
The relevance of low levels of breast cancer cells in PBPC harvests from patients following high-dose chemotherapy remain to be defined in the clinical setting [30] . The role of these cells in causing disease relapse, and the necessity for intervention (i.e., purging of the stem cell product), are issues that are still controversial and require further investigation. Long term follow-up is needed to determine whether RT-PCR assays will be useful in assessing prognosis, guiding clinical decisions, or in developing novel purging strategies.
